-$0.10 Earnings Per Share Expected for BioScrip Inc (NASDAQ:BIOS) This Quarter

Share on StockTwits

Wall Street brokerages expect BioScrip Inc (NASDAQ:BIOS) to announce earnings of ($0.10) per share for the current quarter, Zacks reports. Two analysts have made estimates for BioScrip’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.12). BioScrip reported earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.23). For the next financial year, analysts forecast that the company will post earnings of ($0.16) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover BioScrip.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $178.96 million for the quarter, compared to analysts’ expectations of $179.23 million. During the same quarter in the prior year, the business posted ($0.12) EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis.

BIOS has been the topic of several analyst reports. BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a research note on Thursday. Barrington Research reiterated a “buy” rating and issued a $4.00 target price on shares of BioScrip in a research note on Friday, May 3rd. TheStreet lowered Red Lion Hotels from a “c” rating to a “d+” rating in a research note on Wednesday, April 3rd. Finally, Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $4.60.

BIOS traded down $0.11 on Friday, hitting $2.78. The company had a trading volume of 532,056 shares, compared to its average volume of 1,177,508. The company has a fifty day simple moving average of $2.36. BioScrip has a 12-month low of $1.56 and a 12-month high of $4.14. The stock has a market cap of $369.54 million, a PE ratio of -5.67 and a beta of 0.68.

Several large investors have recently added to or reduced their stakes in the stock. Maven Securities LTD bought a new position in shares of BioScrip during the fourth quarter valued at approximately $45,000. Caxton Associates LP acquired a new stake in BioScrip in the fourth quarter worth approximately $52,000. SG Americas Securities LLC acquired a new stake in BioScrip in the first quarter worth approximately $49,000. FNY Investment Advisers LLC lifted its position in BioScrip by 840.9% in the first quarter. FNY Investment Advisers LLC now owns 25,000 shares of the company’s stock worth $50,000 after purchasing an additional 22,343 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its position in BioScrip by 205.2% in the first quarter. BNP Paribas Arbitrage SA now owns 26,338 shares of the company’s stock worth $53,000 after purchasing an additional 17,709 shares during the period. Institutional investors and hedge funds own 78.60% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.

Recommended Story: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.